指南与共识呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

女性阻塞性睡眠呼吸暂停诊治专家共识

[Expert consensus on the diagnosis and treatment of obstructive sleep apnea in women].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2024-01-01
一句话结论中国胸科协会睡眠障碍组发布共识,提出34条推荐覆盖13个临床问题,指导女性不同生命阶段OSA的筛查、诊断与治疗。

该共识由中华医学会呼吸病学分会睡眠障碍学组组织多学科专家制定,基于26部指南和共识、121篇英文文献和24篇中文文献,总结了女性不同生命阶段OSA的流行病学、临床特征、诊断、治疗和随访,尤其关注妊娠期OSA相关问题。共识分为流行病学、诊断、治疗和妊娠期OSA四部分,共34条推荐,覆盖13个临床问题,旨在提高对女性OSA的认识和管理。

要点

  • 女性OSA症状不典型,失眠、日间疲劳、晨起头痛、焦虑和噩梦不应忽视,尤其绝经后、肥胖和妊娠期女性。
  • STOP-Bang问卷≥3分联合ESS可提高特异性用于女性OSA筛查,但问卷对女性OSA敏感性差。
  • PSG是诊断金标准;Ⅱ或Ⅲ型便携式监测推荐用于高危无复杂合并症、行动不便或危重无法至睡眠中心、围手术期及高度怀疑OSA的孕妇。
  • NPPV是女性中重度OSA的一线治疗;行为干预和患者教育、选择合适人机界面、改善湿化、及时处理不良反应及远程医疗模式可提高依从性。
  • 妊娠期OSA与先兆子痫、妊娠期高血压疾病、妊娠期糖尿病、早产、新生儿窒息、胎儿生长受限等风险增加相关。

适用人群与场景

  • 女性不同生命阶段:儿童期和青春期、育龄期、妊娠期、围绝经期和绝经后期。
  • 妊娠期女性,尤其是有孕前打鼾或OSA病史者。
  • 多囊卵巢综合征、甲状腺功能减退、肢端肥大症女性应筛查OSA。
  • 从事驾驶和高空作业等职业的女性。
  • 有OSA一级亲属的女性。

诊断标准与关键阈值

  • 成人非妊娠女性OSA诊断和分级标准与成人OSA诊断标准相同;妊娠期OSA诊断和分级见「第四部分:妊娠期OSA」。
  • 妊娠期OSA高危人群:符合以下任一条件者:1)症状:睡眠打鼾、觉醒、晨起头痛、失眠、抑郁、日间过度嗜睡等。

处置流程与药物剂量

  • 所有不同程度OSA的女性患者均可应用一般治疗:减重、饮食控制、运动、体位治疗、减少酒精摄入、慎用镇静催眠药物。
  • NPPV是女性中重度OSA的一线治疗,可解除上气道阻塞、消除睡眠低氧、改善睡眠质量和生活质量、降低相关并发症发生率和死亡率。
  • 提高NPPV依从性:推荐行为干预和患者教育,选择合适人机界面、改善湿化效果、及时处理不良反应、应用远程医疗模式。
  • 其他治疗包括口腔矫治器、上气道手术和舌下神经刺激治疗,在女性中疗效中等;绝经后激素治疗(MHT)对OSA有一定治疗作用,但安全性需进一步评估。
  • NPPV治疗后每6个月或1年随访;手术治疗后第3和第6个月复查PSG评估疗效,疗效差者推荐NPPV等治疗;口腔矫治器治疗后第3和第6个月复查PSG,根据需要调整以巩固长期疗效或转换为NPPV等治疗。
  • 随访中关注AHI、症状和不良反应的改善;推荐通过互联网远程管理NPPV治疗。

红旗征与不能漏的情况

  • 妊娠期OSA与先兆子痫、妊娠期高血压疾病、妊娠期糖尿病、早产、新生儿窒息、胎儿生长受限等风险增加相关。
  • OSA是女性高血压、心脑血管疾病、代谢紊乱、情绪和认知障碍及恶性肿瘤的独立危险因素。

研究设计与关键结果

  • 共识基于26部指南和共识、121篇英文文献和24篇中文文献制定,分为流行病学、诊断、治疗和妊娠期OSA四部分,共34条推荐覆盖13个临床问题。

证据类型、等级与局限

  • 证据类型:专家共识;制定方法:基于26部指南和共识、121篇英文文献和24篇中文文献,由睡眠障碍学组组织多学科专家起草。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 女性OSA症状不典型,应关注打鼾频率及失眠、日间疲劳、晨起头痛、焦虑和噩梦等非典型症状,尤其绝经后、肥胖和妊娠期女性。
  • 筛查工具不能替代客观睡眠监测诊断OSA;STOP-Bang问卷≥3分联合ESS可用于女性OSA筛查,但问卷对女性敏感性差。
  • Ⅱ或Ⅲ型便携式监测推荐用于高危无复杂合并症、行动不便或危重无法至睡眠中心、围手术期及高度怀疑OSA的孕妇。
  • 女性OSA患者医疗费用和合并症风险高于男性,应及时评估和治疗。
  • 妊娠期女性应在妊娠管理和保健中筛查和诊断OSA。

指南或共识出处

  • 专家共识名称:女性阻塞性睡眠呼吸暂停诊治专家共识;发布机构:中国胸科协会睡眠障碍组(Sleep Disorder Group of Chinese Thoracic Society);发表于《中华结核和呼吸杂志》(Zhonghua Jie He He Hu Xi Za Zhi)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Obstructive sleep apnea (OSA) shows sex differences in the pathophysiology, epidemiology, and clinical presentation. Women have different characteristics of OSA at different life stages. Based on 26 guidelines and consensus, 121 English literatures, and 24 Chinese literatures, the Sleep Disorder Group of Chinese Thoracic Society has drafted a consensus with multidisciplinary experts to summarize the epidemiology, clinical characteristics, diagnosis, treatment, and follow-up of OSA in women at different life stages, particularly issues related to OSA during pregnancy. The consensus is divided into four parts: epidemiology, diagnosis, treatment, and issues for pregnant women with OSA, with 34 recommendations covering 13 clinical issues. The aim was to improve the understanding and managements of OSA in women.Summary of recommendationsQuestion 1: What is the prevalence of OSA in women at different life stages?The prevalence of OSA varies among women at different life stages. Sex differences are not significant in childhood and adolescence. The prevalence of OSA in women of childbearing age is significantly lower than that in men. The prevalence of OSA increases during pregnancy due to changes in hormone levels and the influence of pregnancy physiology, as well as with gestational weeks. In postmenopausal women, the prevalence of OSA increases significantly, and the sex differences are no longer significant.Question 2: What are the risk factors for OSA in women at different life stages?The risk factors for OSA in women at different life stages are not identical. (1) Childhood and adolescence: Tonsillar and adenoid hypertrophy, obesity, and craniofacial structural anomalies increase the risk of OSA; (2) Childbearing age: The prevalence of OSA in women is lower than in men. However, obesity, hypothyroidism, acromegaly, and polycystic ovary syndrome increase the risk of OSA, and these patients should be screened for OSA; (3) Pregnancy: hormonal effects, uterine enlargement, and weight changes increase the risk of OSA, especially in those with a history of snoring or OSA before pregnancy; (4) Perimenopausal and post-menopausal periods: Decreased levels of estrogen/progesterone reduce the protective effects on the upper airways, and increase the risk of OSA. Menopause is an important risk factor for OSA in women.Question 3: What are the harms of OSA in women?OSA is an independent risk factor for diseases such as hypertension, cardiovascular and cerebrovascular diseases, metabolic disorders, emotional and cognitive impairments, and malignant tumors in women. OSA during pregnancy has several adverse effects on maternal and infant health, and is associated with increased risks of preeclampsia, hypertensive disorders complicating pregnancy (HDP), gestational diabetes mellitus (HDM), premature birth, neonatal asphyxia, fetal growth restriction, etc.Question 4: What are the clinical symptoms and physical signs of OSA in women?The symptoms of OSA in women are different from those in men. Attention should be paid to whether women snore and the frequency of snoring, especially among postmenopausal and obese women. The atypical symptoms of OSA, including insomnia, daytime fatigue, morning headache, anxiety and nightmares, should not be ignored, especially in postmenopausal, obese, and pregnant women.Question 5: When should women be screened for OSA?(1) Postmenopausal and pregnant women, as well as women with a first-degree relative with OSA. It should be noted that the clinical symptoms of OSA in women are not typical; (2) Women with polycystic ovary syndrome, hypothyroidism, and acromegaly; (3) Women engaged in various occupations, including driving and working at heights.Question 6: How to screen OSA in women?Many screening tools and questionnaires can be used to screen for OSA, but should not be used to diagnose OSA in the absence of objective sleep tests. (1) Questionnaires and screening tools: The STOP-Bang questionnaire targeting the general population has higher sensitivity than Berlin Questionnaire (BQ), Epworth Sleepiness Scale (ESS), and others. STOP Bang≥3 points combined with ESS can further improve its specificity and can be used for OSA screening in women. However, the questionnaire has poor sensitivity for female OSA. Type Ⅳ monitoring devices can be used for OSA screening in women with a weak recommendation; (2) PSG is the gold standard for diagnosis. Type Ⅱ or Ⅲ portable monitoring (PM) devices are recommended for the diagnosis of OSA in women in the following conditions: 1) Diagnosis of high-risk OSA patients without complex comorbidities; 2) OSA patients who are immobile or critically ill and unable to undergo PSG monitoring in a sleep center; 3) Diagnosis of perioperative OSA patients; 4) Pregnant women with high suspicion of OSA.Question 7: How to diagnose OSA in women?The diagnostic and grading criteria for adult non-pregnant women with OSA are the same as the diagnostic criteria for adult OSA; for diagnosis and grading of OSA in pregnant women, see "Section 4: OSA in Pregnancy".Question 8: How to treat OSA in women?For all the OSA patients with varying degrees of severity in women, the general treatment can be applied: weight loss, dietary control, exercise, position therapy, reduction of alcohol intake, and cautious use of sedative and hypnotic drugs. Medical costs and the risk of comorbidities with OSA in women are higher than those in men. Therefore, OSA patients in women should be promptly evaluated and treated.Question 9: How to optimize non-invasive positive pressure ventilation (NPPV) treatment and improve compliance for OSA patients in women?(1) NPPV is the first-line treatment for moderate to severe OSA in women. It can relieve upper airway obstruction, eliminate sleep hypoxia, improve sleep quality and quality of life, and reduce the incidence of related complications and mortality; (2) To improve compliance with NPPV treatment, behavioral interventions and patient education are recommended. Selecting an appropriate human-machine interface, improving the humidification effect, promptly handling adverse reactions, and applying remote medical models may improve the compliance.Question 10: What are the other options for OSA treatment in women?Other treatment methods include oral appliances, upper airway surgery, and sublingual nerve stimulation therapy, which have moderate therapeutic effects in women. Postmenopausal hormone therapy (MHT) in women has a certain therapeutic effect on OSA, but its safety needs further evaluation.Question 11: What is follow-up evaluation for OSA in women?(1) Follow-up every 6 months or 1 year after receiving NPPV treatment; (2) PSG should be rechecked at the 3rd and 6th months after surgical treatment to evaluate the therapeutic effects. For patients with poor therapeutic effects after surgery, it is recommended to use treatments such as NPPV; (3) PSG should be rechecked at the 3rd and 6th months after oral appliance treatment. Oral appliances should be adjusted as needed to consolidate long-term efficacy, or switched to a treatment such as NPPV; (4) During follow-up, attention should be paid to the improvement of apnea hypopnea index(AHI), symptoms, and side effects; (5) It is recommended that NPPV treatment be remotely managed via the internet, which can provide high-quality and comprehensive sleep care; (6) Follow-up of OSA during pregnancy can be found in "Section 4: OSA in Pregnancy ".Question 12: How to diagnose and evaluate OSA during pregnancy?OSA during pregnancy has adverse effects on maternal and infant outcomes. It is recommended that high-risk pregnant women be screened and diagnosed for OSA during pregnancy management and healthcare.(1) Screening of the high-risk population: Individuals who meet any of the following criteria are considered at high risk for OSA during pregnancy. 1) Symptoms: snoring during sleep, arousal, headache in the morning, insomnia, depression, excessive daytime sleepiness, and fatigue; 2) Pregnant women over 35 years old; 3) Physical signs: weight exceeding standard body weight by 20% or more, BMI≥28 kg/m2, and neck circumference>40 cm; anatomical abnormalities of the upper airways, such as nasal obstruction, tonsil hypertrophy, and mandibular retrognathia, etc.; 4) Combined internal medicine diseases, such as refractory hypertension, unknown arrhythmia, chronic congestive heart failure, refractory diabetes and insulin resistance, refractory asthma, hypothyroidism, primary aldosteronism; 5) Those with obstetric related diseases, such as preeclampsia, HDP, GDM, and intrauterine growth restriction of the fetus, and with symptoms of chest tightness and apnea that cannot be explained by other factors, and with previous history of gestational OSA or family history.(2) Screening time: There is currently no strong evidence to support the recommendation for optimal screening time. Given the adverse effects of OSA on mothers and infants, it is recommended that high-risk individuals of OSA be screened for OSA between12 and 18 weeks of pregnancy.(3) Screening tools: The main manifestations of OSA in pregnant women are insomnia and poor sleep quality, whereas daytime drowsiness is often not severe. Various sleep questionnaires and models for OSA in pregnancy have poor sensitivity and specificity. Type Ⅳ and consumer-level monitoring devices are lack of sufficient clinical validation. It is recommended that the results of the above screening tools should only have an indicative role in the diagnosis of OSA during pregnancy.(4) Diagnostic tools: PSG is the gold standard for the diagnosis of OSA in pregnancy. PM may be the first choice diagnostic technique for OSA in pregnancy, and Type Ⅲ monitoring devices are the most commonly used devices.(5) Diagnostic criteria: Diagnosis of OSA during pregnancy should be based on symptoms, signs, and PSG or PM monitoring results. Diagnostic criteria for OSA during pregnancy are as follows: 1) PSG or PM monitoring shows AHI≥5 times/h with symptoms or signs of OSA in women, or with related complications (such as diagnosed hypertension, emotional disorders, unexplained arrhythmias, chronic congestive heart failure, HDP, HDM, intrauterine growth restriction that cannot be explained by other factors, chest tightness and apnea excluding other reasons), or with previous history of OSA or family history of OSA; 2) PSG or PM monitoring shows AHI≥10 times/h in those with less daytime drowsiness (ESS≤9 points).Question 13: How to manage OSA during pregnancy?(1) Once OSA is diagnosed during pregnancy, personalized treatment plans from pregnancy to birth should be developed through collaborative discussions between sleep center professionals, obstetricians, pregnant women, and their families. Multidisciplinary collaboration among anaesthesia, neonatology, and critical care medicine may be required in some cases. A comprehensive management approach should be adopted based on the patient's condition, which includes strengthening weight management, positioning treatment, NPPV treatment, oral appliances, and management of maternal and infant complications; (2) Considering the Regarding continuous weight gain during pregnancy, APAP treatment is more appropriate mode for pregnant women with OSA; (3) Oral appliances are suitable for patients with snoring or mild to moderate OSA, especially those with combined mandibular retraction or NPPV intolerance. However, oral appliances are not recommended as the first-line treatment; (4) It is not recommended to use surgical methods to treat OSA during pregnancy; (5) Follow-up and evaluation: Patients' conditions should be re-evaluated and treatment plans should be adjusted at around 24 weeks of pregnancy. Postpartum PSG or PM monitoring should be repeated to assess the need for continued treatment after delivery.

阻塞性睡眠呼吸暂停(obstructive sleep apnea,OSA)存在性别差异,不同生命阶段女性OSA各具特征。中华医学会呼吸病学分会睡眠呼吸障碍学组联合多学科专家,基于现有指南及共识26部、英文文献121篇、中文文献24篇制订本共识,对女性不同生命阶段OSA的流行病学、临床特征、诊断、治疗与随访,尤其是妊娠期OSA相关问题进行归纳总结,提出推荐意见。共识分为流行病学篇、诊断篇、治疗篇、妊娠期OSA篇四个部分,针对13个临床问题形成34条推荐意见。旨在提高临床医生对女性OSA的认识,指导临床实践。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

参考来源

  1. [Expert consensus on the diagnosis and treatment of obstructive sleep apnea in women]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38858201. doi:10.3760/cma.j.cn112147-20240206-00072

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。